The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice

Robert P Hebbel, Gregory M Vercellotti, Betty S. Pace, Anna Solovey, Rahn Kollander, Chine F. Abanonu, Julia Nguyen, Julie V. Vineyard, John D Belcher, Fuad Abdulla, Shadé Osifuye, John W. Eaton, Robert J. Kelm, Arne Slungaard

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The vascular pathobiology of sickle cell anemia involves inflammation, coagulation, vascular stasis, reperfusion injury, iron-based oxidative biochemistry, deficient nitric oxide (NO) bioavailability, and red cell sickling. These disparate pathobiologies intersect and overlap, so it is probable that multimodality therapy will be necessary for this disease. We have, therefore, tested a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), for efficacy in reducing endothelial activation. We found that pulmonary vascular endothelial VCAM-1 and tissue factor (TF) expression (both are indicators of endothelial activation) are powerfully and significantly inhibited by TSA. This is seen both with pretreatment before the inducing stress of hypoxia/reoxygenation (NY1DD sickle transgenic mouse), and upon longer-term therapy after endothelial activation has already occurred (hBERK1 sickle mouse at ambient air). In addition, TSA prevented vascular stasis in sickle mice, it exhibited activity as an iron chelator, and it induced expression of the antisickling hemoglobin, hemoglobin F. Notably, the TSA analog SAHA (suberoylanilide hydroxaminc acid) that is already approved for human clinical use exhibits the same spectrum of biologic effects as TSA. We suggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and treatment of the chronic vasculopathy of sickle cell anemia.

Original languageEnglish (US)
Pages (from-to)2483-2490
Number of pages8
JournalBlood
Volume115
Issue number12
DOIs
StatePublished - Mar 25 2010

Fingerprint

trichostatin A
Histone Deacetylase Inhibitors
Transgenic Mice
Blood Vessels
Chemical activation
Sickle Cell Anemia
Iron
Fetal Hemoglobin
Biochemistry
Acids
Vascular Cell Adhesion Molecule-1
Thromboplastin
Chelating Agents
Coagulation
Reperfusion Injury
Biological Availability
Nitric Oxide
Hemoglobins
Air
Cells

Cite this

The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. / Hebbel, Robert P; Vercellotti, Gregory M; Pace, Betty S.; Solovey, Anna; Kollander, Rahn; Abanonu, Chine F.; Nguyen, Julia; Vineyard, Julie V.; Belcher, John D; Abdulla, Fuad; Osifuye, Shadé; Eaton, John W.; Kelm, Robert J.; Slungaard, Arne.

In: Blood, Vol. 115, No. 12, 25.03.2010, p. 2483-2490.

Research output: Contribution to journalArticle

Hebbel, Robert P ; Vercellotti, Gregory M ; Pace, Betty S. ; Solovey, Anna ; Kollander, Rahn ; Abanonu, Chine F. ; Nguyen, Julia ; Vineyard, Julie V. ; Belcher, John D ; Abdulla, Fuad ; Osifuye, Shadé ; Eaton, John W. ; Kelm, Robert J. ; Slungaard, Arne. / The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. In: Blood. 2010 ; Vol. 115, No. 12. pp. 2483-2490.
@article{45d5dba763d7446fb6452552d16144f7,
title = "The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice",
abstract = "The vascular pathobiology of sickle cell anemia involves inflammation, coagulation, vascular stasis, reperfusion injury, iron-based oxidative biochemistry, deficient nitric oxide (NO) bioavailability, and red cell sickling. These disparate pathobiologies intersect and overlap, so it is probable that multimodality therapy will be necessary for this disease. We have, therefore, tested a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), for efficacy in reducing endothelial activation. We found that pulmonary vascular endothelial VCAM-1 and tissue factor (TF) expression (both are indicators of endothelial activation) are powerfully and significantly inhibited by TSA. This is seen both with pretreatment before the inducing stress of hypoxia/reoxygenation (NY1DD sickle transgenic mouse), and upon longer-term therapy after endothelial activation has already occurred (hBERK1 sickle mouse at ambient air). In addition, TSA prevented vascular stasis in sickle mice, it exhibited activity as an iron chelator, and it induced expression of the antisickling hemoglobin, hemoglobin F. Notably, the TSA analog SAHA (suberoylanilide hydroxaminc acid) that is already approved for human clinical use exhibits the same spectrum of biologic effects as TSA. We suggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and treatment of the chronic vasculopathy of sickle cell anemia.",
author = "Hebbel, {Robert P} and Vercellotti, {Gregory M} and Pace, {Betty S.} and Anna Solovey and Rahn Kollander and Abanonu, {Chine F.} and Julia Nguyen and Vineyard, {Julie V.} and Belcher, {John D} and Fuad Abdulla and Shad{\'e} Osifuye and Eaton, {John W.} and Kelm, {Robert J.} and Arne Slungaard",
year = "2010",
month = "3",
day = "25",
doi = "10.1182/blood-2009-02-204990",
language = "English (US)",
volume = "115",
pages = "2483--2490",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice

AU - Hebbel, Robert P

AU - Vercellotti, Gregory M

AU - Pace, Betty S.

AU - Solovey, Anna

AU - Kollander, Rahn

AU - Abanonu, Chine F.

AU - Nguyen, Julia

AU - Vineyard, Julie V.

AU - Belcher, John D

AU - Abdulla, Fuad

AU - Osifuye, Shadé

AU - Eaton, John W.

AU - Kelm, Robert J.

AU - Slungaard, Arne

PY - 2010/3/25

Y1 - 2010/3/25

N2 - The vascular pathobiology of sickle cell anemia involves inflammation, coagulation, vascular stasis, reperfusion injury, iron-based oxidative biochemistry, deficient nitric oxide (NO) bioavailability, and red cell sickling. These disparate pathobiologies intersect and overlap, so it is probable that multimodality therapy will be necessary for this disease. We have, therefore, tested a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), for efficacy in reducing endothelial activation. We found that pulmonary vascular endothelial VCAM-1 and tissue factor (TF) expression (both are indicators of endothelial activation) are powerfully and significantly inhibited by TSA. This is seen both with pretreatment before the inducing stress of hypoxia/reoxygenation (NY1DD sickle transgenic mouse), and upon longer-term therapy after endothelial activation has already occurred (hBERK1 sickle mouse at ambient air). In addition, TSA prevented vascular stasis in sickle mice, it exhibited activity as an iron chelator, and it induced expression of the antisickling hemoglobin, hemoglobin F. Notably, the TSA analog SAHA (suberoylanilide hydroxaminc acid) that is already approved for human clinical use exhibits the same spectrum of biologic effects as TSA. We suggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and treatment of the chronic vasculopathy of sickle cell anemia.

AB - The vascular pathobiology of sickle cell anemia involves inflammation, coagulation, vascular stasis, reperfusion injury, iron-based oxidative biochemistry, deficient nitric oxide (NO) bioavailability, and red cell sickling. These disparate pathobiologies intersect and overlap, so it is probable that multimodality therapy will be necessary for this disease. We have, therefore, tested a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), for efficacy in reducing endothelial activation. We found that pulmonary vascular endothelial VCAM-1 and tissue factor (TF) expression (both are indicators of endothelial activation) are powerfully and significantly inhibited by TSA. This is seen both with pretreatment before the inducing stress of hypoxia/reoxygenation (NY1DD sickle transgenic mouse), and upon longer-term therapy after endothelial activation has already occurred (hBERK1 sickle mouse at ambient air). In addition, TSA prevented vascular stasis in sickle mice, it exhibited activity as an iron chelator, and it induced expression of the antisickling hemoglobin, hemoglobin F. Notably, the TSA analog SAHA (suberoylanilide hydroxaminc acid) that is already approved for human clinical use exhibits the same spectrum of biologic effects as TSA. We suggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and treatment of the chronic vasculopathy of sickle cell anemia.

UR - http://www.scopus.com/inward/record.url?scp=77950549033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950549033&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-02-204990

DO - 10.1182/blood-2009-02-204990

M3 - Article

VL - 115

SP - 2483

EP - 2490

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -